avelumab + sacituzumab govitecan

Avelumab + sacituzumab govitecan is an investigational combination therapy being studied for the treatment of advanced solid tumors, including metastatic triple-negative breast cancer and advanced urothelial carcinoma. Avelumab is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Sacituzumab govitecan is an antibody-drug conjugate composed of a humanized anti-Trop-2 monoclonal antibody linked to SN-38, the active metabolite of irinotecan, which inhibits DNA topoisomerase I and induces DNA damage-mediated cell death in Trop-2-expressing tumor cells. The combination aims to leverage both immunotherapy (avelumab) and targeted cytotoxicity (sacituzumab govitecan) for synergistic anti-cancer effects[1][5][8].